GlassScriptPhysician profile
Tanya Roberts
NPI 1851383814
$2,869.44
in general payments reported to CMS, 2019-2025
28 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $291 · 2021: $214 · 2022: $417 · 2023: $214 · 2024: $400 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $377.81 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $320.62 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $242.50 | 2019-2025 | Flumist Quadrivalent, Airsupra, Farxiga |
| Abbott Laboratories | $218.13 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.79 | 2022 | |
| Eisai INC. | $181.20 | 2019-2024 | |
| Pfizer INC. | $155.46 | 2019-2020 | |
| Ethicon INC. | $146.94 | 2024 | Monarch Platform |
| Phathom Pharmaceuticals, INC. | $114.30 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.77 | 2020 | |
| Axsome Therapeutics, INC. | $95.25 | 2023 | Auvelity |
| Novartis Pharmaceuticals Corporation | $88.43 | 2019 | |
| Medtronic Vascular, INC. | $81.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.24 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $66.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $60.47 | 2019-2020 | |
| Amarin Pharma, INC. | $54.86 | 2019-2020 | |
| Astellas Pharma US INC | $44.63 | 2020-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.81 | 2025 | Jardiance |
| Amgen INC. | $32.16 | 2025 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $29.57 | 2019-2025 | Contrave |
| Abbvie INC. | $25.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.00 | 2019 | |
| Biotronik Nro, INC. | $23.53 | 2025 | Prospera |
| Almatica Pharma LLC | $23.21 | 2025 | Loreev Xr |
| Lilly USA, LLC | $22.09 | 2025 | Kisunla |
| Xeris Pharmaceuticals, INC. | $17.06 | 2025 | Gvoke Hypopen |
| Nalpropion Pharmaceuticals LLC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.